HUTCHMED Reports the Completion of Patient Enrollment of Amdizalisib in P-II Registration Trial for Follicular Lymphoma in China
Shots:
- The company has completed the patient enrollment in the P-II registration trial evaluating the efficacy & safety of amdizalisib as monotx. in 108 patients with r/r FL or MZL in ~35 sites in China
- The 1EPs of the trial is ORR & the 2EPs incl. CRR, PFS, time to response, and DoR. The results are expected in H2’23
- If the results from the P-II trial are positive, the company plans for marketing authorization of amdizalisib for r/r FL in China. Amdizalisib (HMPL-689) is a novel, selective, and potent oral inhibitor targeting the isoform PI3Kδ & is being studied in the P-II study in combination with tazemetostat (a methyltransferase inhibitor of EZH2) for r/r lymphoma
Ref: Globenewswire | Image: HUTCHMED
Related News:- Hutchmed's Amdizalisib (HMPL-689) Receives Breakthrough Therapy Designation for the Treatment of R/R Follicular Lymphoma in China
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
